Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$23.38 USD
+0.25 (1.08%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $23.38 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
APLS 23.38 +0.25(1.08%)
Will APLS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLS
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
Repligen (RGEN) Lags Q2 Earnings Estimates
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
Other News for APLS
50 Day Moving Average Resistance appears for APLS after 2.9% move
Fell Below 50 Day Moving Average appears for APLS after 2.34% move
Is APLS ready to move higher? 50 Day Moving Average Support shows up after sliding 1.85%
APLS Crosses Below Key Moving Average Level
NR7 appears for APLS after 2.17% move